Cogent Biosciences/$COGT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Cogent Biosciences
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
- Ticker
- $COGT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 258
- Headquarters
- Waltham, United States
- Website
- www.cogentbio.com
COGT Metrics
BasicAdvanced
$5.1B
-
-$2.43
0.31
-
Price and volume
Market cap
$5.1B
Beta
0.31
52-week high
$43.73
52-week low
$13.78
Average daily volume
2.2M
Financial strength
Current ratio
13.573
Quick ratio
13.362
Long term debt to equity
0.456
Total debt to equity
0.459
Interest coverage (TTM)
-75.14%
Profitability
EBITDA (TTM)
-386.457
Management effectiveness
Return on assets (TTM)
-43.84%
Return on equity (TTM)
-109.74%
Valuation
Price to book
10.84
Price to tangible book (TTM)
10.84
Price to free cash flow (TTM)
-14.801
Free cash flow yield (TTM)
-6.76%
Free cash flow per share (TTM)
-1.995
Growth
Earnings per share change (TTM)
-3.49%
3-year earnings per share growth (CAGR)
3.39%
What the Analysts think about COGT
Analyst ratings (Buy, Hold, Sell) for Cogent Biosciences stock.
Analyst projections of the future price of Cogent Biosciences stock.
Bulls say / Bears say
In the Phase 3 PEAK trial, bezuclastinib plus sunitinib extended median progression-free survival to 16.5 months, versus 9.2 months with sunitinib alone, and raised response rates from 26% to 46%. The FDA granted the GIST application Priority Review. (GlobeNewswire)
In the Phase 2 SUMMIT trial for non-advanced systemic mastocytosis, bezuclastinib improved symptom scores more than placebo, with a statistically significant 8.9-point placebo-adjusted difference at week 24. The trial met its primary and key secondary endpoints. (Rare Disease Advisor)
In advanced systemic mastocytosis, the APEX trial reported a 65% overall response rate and 79% progression-free survival at 12 months. The FDA accepted Cogent’s application for this additional indication, giving bezuclastinib another potential growth market. (GlobeNewswire)
APEX’s advanced-disease results remain uncertain over longer follow-up: median progression-free and overall survival had not been reached, so the 12-month estimates do not yet show how durable the benefit will be. (GlobeNewswire)
The GIST combination showed more serious liver-enzyme elevations than sunitinib alone: grade 3 or higher ALT/AST increases were reported in 10.8% of patients versus 1.4%. Treatment-related discontinuations were also higher, at 7.4% versus 3.8%. (Merlintrader)
Cogent’s second-quarter net loss widened to $96.4 million from $73.5 million a year earlier, and it raised $73.6 million by selling shares after quarter-end. Continued losses and further equity sales could dilute shareholders, even though the company says its cash should last into late 2028. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 12 Oct 2026.
COGT Financial Performance
Revenues and expenses
COGT Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing COGT
AllUSDEURGBP
Fund name | Fund size | $COGT weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.34% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.34% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.17% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.17% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.